Last --
Change Today 0.00 / 0.00%
Volume 0.0
4565 On Other Exchanges
Symbol
Exchange
4565 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

sosei group corp (4565) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SOSEI GROUP CORP (4565)

Related News

No related news articles were found.

sosei group corp (4565) Related Businessweek News

No Related Businessweek News Found

sosei group corp (4565) Details

Sosei Group Corporation, a biopharmaceutical company, develops and commercializes pharmaceutical drugs worldwide. It offers NorLevo, an oral emergency contraceptive pill. The company’s product pipeline includes Seebri/NVA237, an inhaled long-acting muscarinic antagonist indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD), as well as conducts a Phase III clinical trial program for uncontrolled asthma; and Ultibro/QVA149, an inhalation capsules for the maintenance bronchodilator treatment of COPD. Its product pipeline also comprises SO-1105, an antifungal agent for the treatment of oropharyngeal candidiasis in immunocompromised patients; and APP13002 and APP13007, which are ophthalmic solutions in pre-clinical stage for infectious cornea inflammation, infectious conjunctivitis, etc. Sosei Group Corporation was incorporated in 1990 and is headquartered in Tokyo, Japan.

30 Employees
Last Reported Date: 06/25/14
Founded in 1990

sosei group corp (4565) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

sosei group corp (4565) Key Developments

Sosei Group Corporation Reports Consolidated Earnings Results for the Six Months Quarter Ended September 30, 2014; Provides Earnings Guidance for the Fiscal Year Ending March 31, 2015

Sosei Group Corporation reported consolidated earnings results for the six months quarter ended September 30, 2014. The group reported revenue of JPY 565 million against JPY 1,589 million a year ago. Operating loss was JPY 85 million against operating income of JPY 894 million a year ago. Net income before tax of income taxes were JPY 75 million against JPY 895 million a year ago. Net income was JPY 28 million against JPY 894 million a year ago. Net income attributable to owners of the parent company was JPY 28 million against JPY 894 million a year ago. Net income per diluted share was JPY 2.04 against JPY 73.78 million a year ago. Net income before income taxes was JPY 895,924,000 against JPY 75,487 million a year ago. Net cash used in operating activities was JPY 368,591,000 against net cash from operating activities of JPY 239,594,000 a year ago. Purchases of property, plant and equipment was JPY 7,766,000 against JPY 5,575,000 a year ago. For the fiscal ending March 31, 2015, the company expects revenue of JPY 3,300 million, operating income of JPY 2,000 million, net income before income taxes of JPY 2,000 million and net income attributable to owners of parent of JPY 2,000 million.

Sosei Group Corporation Announces Positive Results from Three Clinical Trials Presented at ERS 2014

Sosei Group Corporation confirmed the new data from three clinical trials presented by Novartis at the European Respiratory Society (ERS) International Congress, September 6-10, in Munich, Germany. The LANTERN study demonstrated that once-daily Ultibro Breezhaler (indacaterol/glycopyrronium bromide) was superior in reducing exacerbations (flare ups) and improving lung function compared to twice-daily Seretide Accuhaler (salmeterol/fluticasone (SFC)), in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). The study showed Ultibro Breezhaler significantly reduced the rate of moderate-to-severe exacerbations by 31% compared to SFC1, in moderate-to- severe COPD patients with a history of one exacerbation or none in the previous year. In addition, Ultibro Breezhaler patients had significantly increased lung function (trough FEV1 0.075 L (p<0.001); AUC0-4h 0.122 L (p<0.001)), as compared to SFC after 26 weeks of treatment. The safety profile of Ultibro Breezhaler was comparable to SFC1. The new findings from LANTERN support the use of Ultibro Breezhaler as an alternative steroid-free treatment to SFC in moderate-to-severe COPD patients1. This approach is consistent with the Global Initiative for Chronic Obstructive Lung Disease 2014 guidelines3. Analyses from the QUANTIFY study demonstrated that Ultibro Breezhaler significantly improved lung function and shortness of breath in patients with moderate-to-severe COPD, compared to the combination of tiotropium plus formoterol2. Results also showed that Ultibro Breezhaler is comparable to tiotropium plus formoterol in improving health-related quality of life2. Data from the GLISTEN trial showed that Seebri Breezhaler (glycopyrronium bromide) when added to LABA/ICS provided significant improvements in lung function, health status and rescue medication use in moderate-to-severe COPD patients when compared to LABA/ICS alone3. This study provides much-needed evidence for add-on therapy to LABA/ICS in COPD, to support physicians care choices where very little data exist4. The safety profiles of Ultibro Breezhaler and Seebri Breezhaler were similar to those of their respective study comparators in the LANTERN, QUANTIFY and GLISTEN studies. COPD symptoms can have a major negative impact on a patient's ability to breathe and function, reducing their quality of life. Essential daily activities such as climbing stairscan become very difficult as the condition gradually worsens6. There is a need for newer treatment options in COPD because many patients remain symptomatic despite medicaltherapy.

Sosei Group Corporation Reports Consolidated Earnings Results for the First Quarter Ended June 30, 2014; Provides Earnings Guidance for Fiscal Ending March 31, 2015

Sosei Group Corporation reported consolidated earnings results for the first quarter ended June 30, 2014. The group reported revenue of ¥236 million, operating loss of ¥79 million, net income before tax of ¥103 million, net loss attributable to owners of parent of ¥104 million or ¥7.57 per basic share against revenue of ¥70 million, operating loss of ¥224 million, net income before tax of ¥221 million, net loss attributable to owners of parent of ¥222 million or ¥18.65 per basic share a year ago. Revenue increase was mainly due to increase of royalties from Seebri®(NVA237) and Ultibro®(QVA149). Net cash provided by operating activities was ¥321,150,000 against ¥302,664,000 a year ago. Purchases of property, plant and equipment was ¥3,795,000 against ¥7,766,000 a year ago. For fiscal ending March 31, 2015, the company expects revenue of ¥3,300 million, operating loss of ¥2,000 million, net income before tax of ¥2,000 million, net income attributable to owners of parent of ¥2,000 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4565:JP ¥4,285.00 JPY +130.00

4565 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4565.
View Industry Companies
 

Industry Analysis

4565

Industry Average

Valuation 4565 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 51.3x
Price/Book 3.7x
Price/Cash Flow 89.4x
TEV/Sales 44.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SOSEI GROUP CORP, please visit www.sosei.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.